Study of Thymus and T- cell Development and Tumor Immunology

Sareh Sangy, Fatemeh Alsadat Miryousefi Ata, Faegheh Miryousefiata

Abstract


Monoclonal antibodies have proven to be effective therapeutic agents for a wide range of human cancers. However, unlike other modes of antibody action, the capacity of antibodies to activate tumor antigen-specific immune responses has received less attention. The rationale and evidence for generating anti-cancer antibodies that can induce host tumor antigen-specific immune responses are described in this paper. This can be performed by stimulating the idiotypic network, generating antibody-dependent cellular cytotoxicity, or boosting antibody-targeted cross-presentation of tumor antigens. To improve the clinical benefits of antibody therapy for human cancer, future therapeutic modifications or combinations should be able to extend, magnify, and shape these immune responses.


Keywords


monoclonal antibody; dendritic cells; cross presentation; anti-idiotype

Full Text:

PDF

References


. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825–33.

. Kaminski MS, Estes J, Zasadny KR, et al. Radio immunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood. 2000;96: 1259–66.

. Coiffier B. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin’s lymphoma. Semin Oncol. 2002;29(2 Suppl 6):18–22.

. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2003;20:2453–63.

. Sievers EL, Appelbaum FR, Spielberger RT, et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood. 1999;93:3678–84.

. Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med. 2001;345:241–47.

. Cobleigh MA, Vogel Cl, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639–48.

. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–92.

. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719–26.

. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–84.

. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42.

. Miller RA, Maloney DG, Warnke R, et al. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Eng J Med. 1982;306:517–22.

. Leonard JP, Link BK. Immunotherapy of non-Hodgkin’s lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab) Semin Oncol. 2002;29(1 Suppl 2):81–86.

. Lundin J, Kimby E, Bjorkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL) Blood. 2002;100:768–73.

. Figlin RA, Belldegrun AS, Crawford J, Lohner M, Roskos L, Yang X-D, Foon K, Schwab G, Weiner L. ABX-EGF, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) in patients with advanced cancer: phase 1 clinical results. Proceedings ASC0. 2002;21:35. Abstract.

. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004; 351:337–45.

. 0egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol. 2002; 3:611–18.

. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 2003; 100:8372–77.

. Steplewski Z, Lubeck MD, Koprowski H. Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cells. Science. 1983; 221:865–67.

. Heijnen IA, van de Winkel JG. Human IgG Fc receptors. Int Rev Immunol. 1997; 16: 29–55.

. Sulica A, Morel P, Metes D, et al. Ig-binding receptors on human NK cells as effecter and regulatory surface molecules. Int Rev Immunol. 2001; 20:371–414.

. Clynes RA, Towers TL, Presta LG, et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med. 2000; 6:443–46.

. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002; 99:754–58.

. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 2003; 21:3940–47.

. Umana P, Jean-Mairet J, Moudry R, et al. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol. 1999; 17:176–80.

. Ghetie V, Ward ES. Multiple roles for the major histocompatibility complex class I-related receptor FcRn. Annu Rev Immunol. 2000; 18:739–66.

. Shields RL, Namenuk AK, Hong K, et al. High-resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem. 2001;276:6591–604.

. Clark JI, Alpaugh RK, von Mehren M, et al. Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment. Cancer Immunol Immunother. 1997;44:265–72.

. Heath WR, Carbone FR. Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol. 2001;19:47–64.

. Amigorena S. Fc gamma receptors and cross-presentation in dendritic cells. J Exp Med. 2002;195:F1–3.

. Dhodapkar KM, Dhodapkar MV. Recruiting dendritic cells to improve antibody therapy of cancer. Proc Natl Acad Sci U S A. 2005;102:6243–64.

. Dhodapkar MV, Dhodapkar KM, Palucka AK. Interactions of tumor cells with dendritic cells: balancing immunity and tolerance. Cell Death Differ. 2008;15:39–50.

. Chamuleau ME, Souwer Y, Van Ham SM, et al. Class II-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome. Cancer Res. 2004;64:5546–50.

. den Haan JM, Bevan MJ. Constitutive versus activation dependent cross presentation of immune complexes by CD8+ and CD8− dendritic cells in vivo. J Exp Med. 2002;196:817–27.

. Dhodapkar KM, Krasovsky J, Williamson B, et al. Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med. 2002;195:125–33.

. Nagata Y, Ono S, Matsuo M, et al. Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations. Proc Natl Acad Sci U S A. 2002;99:10629–34.

. Rafiq K, Bergtold A, Clynes R. Immune complex-mediated antigen presentation induces tumor immunity. J Clin Invest. 2002;110:71–79.

. Schuurhuis DH, Ioan-Facsinay A, Nagelkerken B, et al. Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo. J Immunol. 2002;168:2240–46.

. Selenko N, Majdic O, Jager U, et al. Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies? J Clin Immunol. 2002;22:124–30.

. Akiyama K, Ebihara S, Yada A, et al. Targeting apoptotic tumor cells to FcR provides efficient and versatile vaccination against tumors by dendritic cells. J Immunol. 2003;170:1641–48.

. Sangy S, Miryousefiata F, Bahaoddini A, Dimiati H. The Effects of Gavage Extract of Papaver Rhoeas L on Blood Pressure of MIA Induced Osteoarthritis and Its Interaction with Nitrergic System in male Rat. Budapest International Research in Exact Sciences (BirEx) Journal. Volume 2, No 4 October 2020, Page:458-466. www.bircu-journal.com/index.php/birex. DOI:https://doi.org/10.33258/birex.v2i4.1260

. Zigta, Binyam. (2019).Thermal Radiation, Chemical Reaction and Viscous DissipationEffects on Unsteady MHD Flow of Viscoelastic Fluid Embeddedin a Porous Medium. Budapest International Research in Exact Sciences (BirEx) Journal Volume 1, No 3, July 2019, Page: 35-57www.bircu-journal.com/index.php/birex




DOI: https://doi.org/10.33258/birex.v3i3.2081

Article Metrics

Abstract view : 226 times
PDF - 73 times

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
 

 

Statcounter for Budapest International Research in Exact Sciences (BirEx Journal)